Undisclosed · Other round · Healthtech · Leiden, Netherlands
MIMETAS, a Leiden-based developer of organ-on-a-chip platforms and human tissue models for pharmaceutical research, is now majority-owned by Bruker after the scientific-instrument company announced an undisclosed majority investment. Financial terms were not released. MIMETAS will keep its name and existing management, while former investor InnovationQuarter Capital is selling its stake as part of the transaction.
Human tissue models meet Bruker's analytical stack
MIMETAS builds laboratory systems that let drug researchers grow and study human-relevant tissues under controlled, flowing conditions. Its OrganoPlate platform places membrane-free microfluidic tissue cultures into a standard microtiter-plate format, making the models compatible with imaging, automated handling and higher-throughput screening. The company's wider portfolio includes ready-to-use tissue models, supporting instruments and contract research services for pharmaceutical and biotechnology customers.
Bruker says it plans to connect those models with its technologies in proteomics, metabolomics, nuclear magnetic resonance, preclinical imaging and spatial biology. The commercial logic is an integrated research workflow: MIMETAS can provide the human tissue system in which a compound is tested, while Bruker's tools can measure the molecular and cellular response. If the companies make those layers work together reproducibly, customers may be able to move from an experiment to a richer evidence set without assembling separate platforms and service providers.
That integration still has a demanding execution test. Drug developers need models that are consistent across batches and laboratories, measurements that map cleanly onto each tissue system, and results that improve real programme decisions. Bruker's installed base and analytical breadth can expand MIMETAS' distribution, but adoption will depend on whether combined workflows are easier to validate and operate than today's mix of specialist tools.
A scale-up route through an industrial owner
MIMETAS was established in 2013 as a Leiden University spin-out. InnovationQuarter, which invested during the company's 2018 Series B, says MIMETAS now employs more than 80 people and operates globally. The majority investment gives Bruker control of a company with an existing product and service portfolio rather than an early research project, while leaving the MIMETAS brand and management in place.
For MIMETAS, the transaction creates a route into Bruker's worldwide commercial and technical network. For Bruker, it adds the biological model upstream of its measurement systems. The strategic value will be demonstrated if that combination turns organ-on-a-chip experiments into repeatable workflows that pharmaceutical teams use across disease research, compound evaluation and safety testing.
Sources checked:
Bruker announcement · MIMETAS announcement · InnovationQuarter note · Tech.eu Funding Explorer
Image: MIMETAS / Bruker, via the official company announcement.
